Drugs / NH002
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07314385 | Jan 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04185246 | Nov 2019 → Jul 2020 | heart disorder | Trust Bio-sonics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06815627 | Mar 2025 → Feb 2027 expected | heart disorder | Trust Bio-sonics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NH002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185246 ↗ |
| Known as | Perflutren Lipid Microspheres | “NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms” NCT04185246 ↗2“NH002 (Perflutren Lipid Microspheres) Injectable Suspension” NCT06815627 ↗ “NH002 (Perflutren Lipid Microspheres) Injectable Suspension” NCT07314385 ↗ |
| Modality | Diagnostic / imaging agent | “NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent” NCT04185246 ↗ |
| Route | Intravenous | “intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg” NCT04185246 ↗ |